UK experiences a 'baby boom' of new life sciences ventures2 Dec 2019
Unprecedented levels of investment cited as a major force driving the expansion.
BioCity, the pioneering life science incubator and business collective has released its biennial publication, the UK Life Science Start-Up Report, an in-depth analysis of emerging businesses within the life sciences across the UK.
The report has collected, analysed and interpreted data for nearly a decade and a half, and is a key publication for the life science industry.
Authored by BioCity Chairman and former CEO, Dr Glenn Crocker MBE, the report looks at the prevalence of life science start-ups in the UK over the past 5 years and the broader landscape in which they operate to also asses the quality of UK life science start-ups. By analysing the number of start-ups by region, area of scientific focus, funding, investment and university association, the report creates a broad picture of the current health and future of, the industry.
The report documents an unprecedented period of growth for the life sciences, thanks in part to a change in the funding landscape, expressed in a four-fold increase to £2.8B of investment in early-stage ventures, compared to the previous 5-year period.
Multiple factors are highlighted as driving this expansion, but of greatest impact was the emergence of a number of significant venture funds able and willing to make very large investments in early-stage businesses.
Also identified as a contributing factor is the increasing use of smaller companies and academia as sources of innovation by large pharmaceuticals aiming to counteract falling R&D productivity. The report documents a rise in the number of global players establishing or sponsoring accelerators and incubators and making investments through their corporate venturing arms.
Simultaneously, many universities such as Bristol, Newcastle and Aberdeen introduced a gear change in spin-out formation, while a supportive local public sector reinforced the growth. That these regions have all recently or will soon, open, their first life science incubators, the report posits, is not coincidental.
Dr Glenn Crocker said: “Both the number of companies starting up and the amount invested in them has taken off. We have seen a 50% increase in the number of companies and a four-fold increase in investment going into them; this will likely result in a substantial increase in the demand for space. We estimate that this cohort of businesses alone could require 1.4 million sq. ft of specialist facilities over the next 5 years. One consequence of this demand growth is that real estate investors are being increasingly attracted to the sector.”
2019, the year that got serialization done!
17 Dec 2019
The past 12 months have been busy as many companies fought to comply with serialization regulations.Read more
Edible barcodes - it's Tru!
10 Dec 2019
Smart tags on pills set to improve supply chain security and patient adherence.Read more
US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report
9 Dec 2019
The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceuti...Read more
UK’s life sciences sector continues to attract talent despite Brexit fear
26 Nov 2019
The largest area of growth has been within biotechnology companies, where job openings increased by 35%.Read more
Winners of the 16th Pharma Awards
11 Nov 2019
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.Read more
‘FDA should withdraw ANDAs’ says expert
21 Oct 2019
CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.Read more
Sanofi opens its first digitally-enabled, continuous manufacturing facility
15 Oct 2019
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.Read more
EC approves its first plant-derived cannabis-based medicine
24 Sep 2019
Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.Read more
Integrating glucose sensing and insulin delivery technologies
18 Sep 2019
Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin.Read more
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation